Advice
in the absence of a submission from the holder of the marketing authorisation:
denosumab (Prolia®) is not recommended for use within NHSScotland.
Indication under review: Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice212KB (PDF)
Medicine details
- Medicine name:
- denosumab (Prolia)
- SMC ID:
- SMC2117
- Indication:
- Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 September 2018